Trials

ICON CA209-9FN: A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone reseptor positive breast cancer

Cancer type: Breast cancer

Phase: II

Principal Investigator: Kyte Jon Amund

Country: NO

Keywords: Norway, Oslo, luminal B breast cancer, nivolumab, ipilimumab, immunogenic chemotherapy

Status: Inclusion completed

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03409198?term=ICON&cond=Breast+Cancer&cntry=NO&rank=1